Genome-wide association study identifies five new schizophrenia loci S Ripke, AR Sanders, KS Kendler, DF Levinson, P Sklar, PA Holmans, ... Nature genetics 43 (10), 969, 2011 | 1639 | 2011 |
Suicide risk in schizophrenia: learning from the past to change the future M Pompili, XF Amador, P Girardi, J Harkavy-Friedman, M Harrow, ... Annals of general psychiatry 6 (1), 1-22, 2007 | 376 | 2007 |
Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients J Nielsen, S Skadhede, CU Correll Neuropsychopharmacology 35 (9), 1997-2004, 2010 | 232 | 2010 |
Psychiatrists’ attitude towards and knowledge of clozapine treatment J Nielsen, M Dahm, H Lublin, D Taylor Journal of psychopharmacology 24 (7), 965-971, 2010 | 190 | 2010 |
Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Nielsen, CU Correll, P Manu, JM Kane The Journal of clinical psychiatry 74 (6), 603-613, 2013 | 184 | 2013 |
Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis B Galling, A Roldán, RE Nielsen, J Nielsen, T Gerhard, M Carbon, ... JAMA psychiatry 73 (3), 247-259, 2016 | 165 | 2016 |
Safety and tolerability of antipsychotic polypharmacy JA Gallego, J Nielsen, M De Hert, JM Kane, CU Correll Expert opinion on drug safety 11 (4), 527-542, 2012 | 160 | 2012 |
The validity of the schizophrenia diagnosis in the Danish Psychiatric Central Research Register is good P Uggerby, SD Østergaard, R Røge, CU Correll, J Nielsen Dan Med J 60 (2), A4578, 2013 | 151 | 2013 |
Optimizing clozapine treatment J Nielsen, P Damkier, H Lublin, D Taylor Acta Psychiatrica Scandinavica 123 (6), 411-422, 2011 | 150 | 2011 |
Assessing QT interval prolongation and its associated risks with antipsychotics J Nielsen, C Graff, JK Kanters, E Toft, D Taylor, JM Meyer CNS drugs 25 (6), 473-490, 2011 | 147 | 2011 |
Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles JI Goldstein, LF Jarskog, C Hilliard, A Alfirevic, L Duncan, D Fourches, ... Nature communications 5 (1), 1-9, 2014 | 145 | 2014 |
Augmentation of clozapine with a second antipsychotic–a meta‐analysis DM Taylor, L Smith, SH Gee, J Nielsen Acta Psychiatrica Scandinavica 125 (1), 15-24, 2012 | 129 | 2012 |
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta‐analysis and meta‐regression analysis B Galling, A Roldan, K Hagi, L Rietschel, F Walyzada, W Zheng, XL Cao, ... World Psychiatry 16 (1), 77-89, 2017 | 116 | 2017 |
Risk factors for ileus in patients with schizophrenia J Nielsen, JM Meyer Schizophrenia bulletin 38 (3), 592-598, 2012 | 110 | 2012 |
Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? R Røge, BK Møller, CR Andersen, CU Correll, J Nielsen Schizophrenia research 140 (1-3), 204-213, 2012 | 107 | 2012 |
Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management S Fanoe, D Kristensen, A Fink-Jensen, HK Jensen, E Toft, J Nielsen, ... European heart journal 35 (20), 1306-1315, 2014 | 103 | 2014 |
Abuse potential of pregabalin O Schjerning, M Rosenzweig, A Pottegård, P Damkier, J Nielsen CNS drugs 30 (1), 9-25, 2016 | 102 | 2016 |
Worldwide differences in regulations of clozapine use J Nielsen, C Young, P Ifteni, T Kishimoto, YT Xiang, PFJ Schulte, ... CNS drugs 30 (2), 149-161, 2016 | 87 | 2016 |
Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine-or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical … JR Larsen, L Vedtofte, MSL Jakobsen, HR Jespersen, MI Jakobsen, ... JAMA psychiatry 74 (7), 719-728, 2017 | 85 | 2017 |
DAI-10 is as good as DAI-30 in schizophrenia RE Nielsen, E Lindström, J Nielsen, S Levander European Neuropsychopharmacology 22 (10), 747-750, 2012 | 85 | 2012 |